Enhanced anti-tumour effects of Vinca alkaloids given separately from cytostatic therapies

British Journal of Pharmacology

Volumn 168, Issue 7, 2013, Pages 1558-1569

  Ehrhardt, H ^a,b   Pannert, L ^a   Pfeiffer, S ^a   Wachter, F ^a   Amtmann, E ^c   Jeremias, I ^a,b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

application schedule; cell cycle arrest; doxorubicin; p53; vincristine

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAFFEINE; CYCLINE; CYTOSTATIC AGENT; DEXAMETHASONE; DOXORUBICIN; NAVELBINE; PLACEBO; PROTEIN P53; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOMA CELL; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE CHECKPOINT; CELL CYCLE PROGRESSION; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG ANTAGONISM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INHIBITION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GAMMA IRRADIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; KIDNEY CARCINOMA; MONOTHERAPY; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RNA INTERFERENCE; SOLID TUMOR; TUMOR CELL; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANIMALS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL DIVISION; CELL LINE, TUMOR; DEXAMETHASONE; DOXORUBICIN; DRUG ANTAGONISM; FEMALE; GAMMA RAYS; HUMANS; MICE; MICE, NUDE; MITOSIS; NEOPLASM TRANSPLANTATION; VINCRISTINE;

EID: 84875144889     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12068     Document Type: Article

References (40)

1. Akutsu M, Furukawa Y, Tsunoda S, Izumi T, Ohmine K, Kano Y, (2002). Schedule-dependent synergism and antagonism between methotrexate and cytarabine against leukemia cell lines in vitro. Leukemia 16: 1808-1817.
2. Anastasov N, Klier M, Koch I, Angermeier D, Höfler H, Fend F, et al,. (2009). Efficient shRNA delivery into B and T lymphoma cells using lentiviral vector-mediated transfer. J Hematop 2: 9-19.
3. Baader E, Toloczko A, Fuchs U, Schmid I, Beltinger C, Ehrhardt H, et al,. (2005). TRAIL-mediated proliferation of tumor cells with receptor-close apoptosis defects. Cancer Res 65: 7888-7895.
4. Barone C, Landriscina M, Quirino M, Basso M, Pozzo C, Schinzari G, et al,. (2007). Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial. Br J Cancer 96: 21-28.
5. Bendall LJ, (2011). It's all in the timing. Blood 118: 5983-5984.
6. Benz EJ Jr, Nathan DG, Amaravadi RK, Danial NN, (2007). Targeting the cell death-survival equation. Clin Cancer Res 13: 7250-7253.
7. Bonadonna G, Zambetti M, Valagussa P, (1995). Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 273: 542-547.
8. Bonadonna G, Zambetti M, Moliterni A, Gianni L, Valagussa P, (2004). Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer. J Clin Oncol 22: 1614-1620.
9. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al,. (1998). Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501.
10. Dy GK, Adjei AA, (2008). Systemic cancer therapy: evolution over the last 60 years. Cancer 113: 1857-1887.
11. Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin KM, Jeremias I, (2003). TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NFκB. Oncogene 22: 3842-3852.
12. Ehrhardt H, Haecker S, Wittmann S, Maurer M, Borkhardt A, Toloczko A, et al,. (2008). Cytotoxic drug-induced, p53-mediated upregulation of Caspase-8 in tumor cells. Oncogene 27: 783-793.
13. Ehrhardt H, Schrembs D, Moritz C, Wachter F, Haldar S, Graubner U, et al,. (2011a). Optimized anti-tumor effects of anthracyclines plus vinca alkaloids using a novel, mechanism-based application schedule. Blood 118: 6123-6131.
14. Ehrhardt H, Wachter F, Maurer M, Stahnke K, Jeremias I, (2011b). Important role of Caspase-8 for chemo-sensitivity of ALL cells. Clin Cancer Res 17: 7605-7613.
15. Ehrhardt H, Höfig I, Wachter F, Obexer P, Fulda S, Terziyska N, et al,. (2012). NOXA as critical mediator for drug combinations in polychemotherapy. Cell Death Dis 3: e327.
16. Ewald JA, Desotelle JA, Wilding G, Jarrard DF, (2010). Therapy-induced senescence in cancer. J Natl Cancer Inst 102: 1536-1546.
17. Frei E, (1985). Curative cancer chemotherapy. Cancer Res 45: 6523-6537.
18. Jänicke RU, Engels IH, Dunkern T, Kaina B, Schulze-Osthoff K, Porter AG, (2001). Ionizing radiation but not anticancer drugs causes cell cycle arrest and failure to activate the mitochondrial death pathway in MCF-7 breast cancer cells. Oncogene 20: 5043-5053.
19. Kaspers GJL, Veerman AJP, Pieters R, van, Zantwijk I, Hählen K, van, Wering ER, (1995). Drug combination testing in acute lymphoblastic leukemia using the MTT assay. Leuk Res 19: 175-181.
20. Kawamura KI, Grabowski D, Weizer K, Bukowski R, Ganapathi R, (1996). Modulation of vinblastine cytotoxicity by dilantin (phenytoin) or the protein phosphatase inhibitor okadaic acid involves the potentiation of anti-mitotic effects and induction of apoptosis in human tumour cells. Br J Cancer 73: 183-188.
21. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
22. Klier M, Anastasov N, Hermann A, Meindl T, Angermeier D, Raffeld M, et al,. (2008). Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2. Leukemia 22: 2097-2105.
23. Li T, Ling YH, Goldman ID, Perez-Soler R, (2007). Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 13: 3413-3422.
24. Ling YH, el-Naggar AK, Priebe W, Perez-Soler R, (1996). Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicinin synchronized P388 cells. Mol Pharmacol 49: 832-841.
25. Mattern J, Büchler MW, Herr I, (2007). Cell cycle arrest by glucocorticoids may protect normal tissue and solid tumors from cancer therapy. Cancer Biol Ther 6: 1345-1354.
26. Mayer LD, Janoff AS, (2007). Optimizing combination chemotherapy by controlling drug ratios. Mol Interv 7: 216-223.
27. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
28. Mollinedo F, Gajate C, (2003). Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 8: 413-450.
29. Müller HJ, Boos J, (1998). Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 28: 97-113.
30. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C, (1991). A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271-279.
31. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al,. (2007). Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28: 622-629.
32. Ramaswamy S, (2007). Rational design of cancer-drug combinations. N Engl J Med 357: 299-300.
33. Resnick-Silverman L, Manfredi J, (2006). Gene-specific mechanisms of p53 transcriptional control and prospects for cancer therapy. J Cell Biochem 99: 679-689.
34. Rixe O, Fojo T, (2007). Is cell death a critical end point for anticancer therapies or is cytostasis sufficient? Clin Cancer Res 13: 7280-7287.
35. Rozan LM, El-Deiry WS, (2007). p53 downstream target genes and tumor suppression: a classical view in evolution. Cell Death Differ 14: 3-9.
36. Suzuki K, Matsubara H, (2011). Recent advances in p53 research and cancer treatment. J Biomed Biotechnol 2011: 978312.
37. Webb JL, (1963). Effect of more than one inhibitor. In:, Hochster RM, Quastel JH, (eds). Enzyme and Metabolic Inhibitors, Vol. 1. Academic Press: New York, pp. 487-512.
38. Yu J, Zhang L, (2005). The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun 331: 851-858.
39. Yuan J, Krämer A, Matthess Y, Yan R, Spänkuch B, Gätje R, et al,. (2006). Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo. Oncogene 25: 1753-1762.
40. Zhou BB, Elledge SJ, (2000). The DNA damage response: putting checkpoints in perspective. Nature 408: 433-439.